Indinavir influences biological function of dendritic cells and stimulates antifungal immunity

Journal of Leukocyte Biology

Volumn 83, Issue 5, 2008, Pages 1286-1294

  Pericolini, Eva ^a   Cenci, Elio ^a   Gabrielli, Elena ^a   Perito, Stefano ^a   Mosci, Paolo ^a   Bistoni, Francesco ^a   Vecchiarelli, Anna ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

APC; Costimulatory molecules; Cryptococcus neoformans; Immunoregulation; Protease inhibitors

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD8ALPHA ANTIGEN; GLYCOPROTEIN P 15095; INDINAVIR; INTERLEUKIN 12; MESSENGER RNA; PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; FUNGUS GROWTH; HISTOPATHOLOGY; IMMUNITY; IMMUNOREGULATION; IMMUNOSTIMULATION; INFLAMMATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY MECHANISM;

ANIMALS; ANTIFUNGAL AGENTS; ANTIGENS, CD40; ANTIGENS, CD8; ANTIGENS, CD80; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HIV PROTEASE INHIBITORS; INDINAVIR; MICE; MICE, INBRED BALB C;

FILOBASIDIELLA NEOFORMANS; FUNGI;

EID: 46949104143     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0707454     Document Type: Article

References (39)

1. Lim, T. S., Murphy, J. W. (1980) Transfer of immunity to cryptococcosis by T-enriched splenic lymphocytes from Cryptococcus neoformans-sensitized mice. Infect. Immun. 30, 5-11.
2. Good, C. B., Coax, W. A. (1990) Cryptococcal infections in patients with AIDS. N. Engl. J. Med. 322, 701-702.
3. Saag, M. S., Graybill, R. J., Larsen, R. A., Pappas, P. G., Perfect, J. R., Powderly, W. G., Sobel, J. D., Dismukes, W. E. (2000) Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin. Infect. Dis. 30, 710-718.
4. Chen, L. F., Hoy, J., Lewin, S. R. (2007) Ten years of highly active antiretroviral therapy for HIV infection. Med. J. Aust. 186, 146-151.
5. Munro, C. A., Hube, B. (2002) Anti-fungal therapy at the HAART of viral therapy. Trends Microbiol. 10, 173-177.
6. Zingman, B. S. (1996) Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir. N. Engl. J. Med. 334, 1674-1675.
7. Ives, N. J., Gazzard, B. G., Easterbrook, P. J. (2001) The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. J. Infect. 42, 134-139.
8. Cassone, A., De Bernardis, F., Torosantucci, A., Tacconelli, E., Tumbarello, M., Cauda, R. (1999) In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J. Infect. Dis. 180, 448-453.
9. Manfredi, R., Calza, L., Chiodo, F. (2003) AIDS-associated Cryptococcus infection before and after the highly active antiretroviral therapy era: emerging management problems. Int. J. Antimicrob. Agents 22, 449-452.
10. Bobin, S., Bouhour, D., Durupt, S., Boibieux, A., Girault, V., Peyramond, D. (1998) Importance of antiproteases in the treatment of microsporidia and/or cryptosporidia infections in HIV-seropositive patients. Pathol. Biol. (Paris) 46, 418-419.
11. Cressey, T. R., Plipat, N., Fregonese, F., Chokephaibulkit, K. (2007) Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings. Expert Opin. Drug Metab. Toxicol. 3, 347-361.
12. Monari, C., Pericolini, E., Bistoni, G., Cenci, E., Bistoni, F., Vecchiarelli, A. (2005) Influence of indinavir on virulence and growth of Cryptococcus neoformans. J. Infect. Dis. 191, 307-311.
13. Pericolini, E., Cenci, E., Monari, C., Perito, S., Mosci, P., Bistoni, G., Vecchiarelli, A. (2006) Indinavir-treated Cryptococcus neoformans promotes an efficient antifungal immune response in immunosuppressed hosts. Med. Mycol. 44, 119-126.
14. Villadangos, J. A., Heath, W. R. (2005) Life cycle, migration and antigen presenting functions of spleen and lymph node dendritic cells: limitations of the Langerhans cells paradigm. Semin. Immunol. 17, 262-272.
15. Maldonado-Lopez, R., De Smedt, T., Pajak, B., Heirman, C., Thielemans, K., Leo, O., Urbain, J., Maliszewski, C. R., Moser, M. (1999) Role of CD8α+ and CD8α- dendritic cells in the induction of primary immune responses in vivo. J. Leukoc. Biol. 66, 242-246.
16. Bauman, S. K., Nichols, K. L., Murphy, J. W. (2000) Dendritic cells in the induction of protective and nonprotective anticryptococcal cell-mediated immune responses. J. Immunol. 165, 158-167.
17. Gonzalez-Juarrero, M., Orme, I. M. (2001) Characterization of murine lung dendritic cells infected with Mycobacterium tuberculosis. Infect. Immun. 69, 1127-1133.
18. Coker, L. R., Swain, R., Morris, R., McCall, C. O. (2000) Disseminated cryptococcosis presenting as pseudofolliculitis in an AIDS patient. Cutis 66, 207-210.
19. De Heusch, M., Oldenhove, G., Urbain, J., Thielemans, K., Maliszewski, C., Leo, O., Moser, M. (2004) Depending on their maturation state, splenic dendritic cells induce the differentiation of CD4(+) T lymphocytes into memory and/or effector cells in vivo. Eur. J. Immunol. 34, 1861-1869.
20. Maldonado-Lopez, R., De Smedt, T., Michel, P., Godfroid, J., Pajak, B., Heirman, C., Thielemans, K., Leo, O., Urbain, J., Moser, M. (1999) CD8α+ and CD8α- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J. Exp. Med. 189, 587-592.
21. Decken, K., Kohler, G., Palmer-Lehmann, K., Wunderlin, A., Mattner, F., Magram, J., Gately, M. K., Alber, G. (1998) Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans. Infect. Immun. 66, 4994-5000.
22. Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M., Markowitz, M. (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126.
23. Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H., et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122.
24. Azzam, R., Lal, L., Goh, S. L., Kedzierska, K., Jaworowski, A., Naim, E., Cherry, C. L., Wesselingh, S. L., Mills, J., Crowe, S. M. (2006) Adverse effects of antiretroviral drugs on HIV-1-infected and -uninfected human monocyte-derived macrophages. J. Acquir. Immune Defic. Syndr. 42, 19-28.
25. Jevtovic, D., Salemovic, D., Ranin, J., Pesic, I., Zerjav, S., Djurkovic-Djakovic, O. (2005) The dissociation between virological and immunological responses to HAART. Biomed. Pharmacother. 59, 446-451.
26. Notermans, D. W., van Leeuwen, R., Lange, J. M. (1996) Treatment of HIV infection. Tolerability of commonly used antiretroviral agents. Drug Saf. 15, 176-187.
27. Merry, C., Barry, M. G., Mulcahy, F., Halifax, K. L., Back, D. J. (1997) Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients. AIDS 11, F117-F120.
28. Foudraine, N. A., Weverling, G. J., van Gool, T., Roos, M. T., de Wolf, F., Koopmans, P. P., van den Broek, P. J., Meenhorst, P. L., van Leeuwen, R., Lange, J. M., Reiss, P. (1998) Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapy. AIDS 12, 35-41.
29. Tovo, P. A. (2000) Highly active antiretroviral therapy inhibits cytokine production in HIV-uninfected subjects. AIDS 14, 743-744.
30. Whelan, K. T., Lin, C. L., Cella, M., McMichael, A. J., Austyn, J. M., Rowland-Jones, S. L. (2003) The HIV protease inhibitor indinavir reduces immature dendritic cell transendothelial migration. Eur. J. Immunol. 33, 2520-2530.
31. Barillari, G., Sgadari, C., Toschi, E., Monini, P., Ensoli, B. (2003) HIV protease inhibitors as new treatment options for Kaposi's sarcoma. Drug Resist. Updat. 6, 173-181.
32. Palucka, K., Banchereau, J. (2002) How dendritic cells and microbes interact to elicit or subvert protective immune responses. Curr. Opin. Immunol. 14, 420-431.
33. Antachopoulos, C., Roilides, E. (2005) Cytokines and fungal infections. Br. J. Haematol. 129, 583-596.
34. Gruber, A., Wheat, J. C., Kuhen, K. L., Looney, D. J., Wong-Staal, F. (2001) Differential effects of HIV-1 protease inhibitors on dendritic cell immunophenotype and function. J. Biol. Chem. 276, 47840-47843.
35. Vecchiarelli, A. (2000) Immunoregulation by capsular components of Cryptococcus neoformans. Med. Mycol. 38, 407-417.
36. Fujii, S., Liu, K., Smith, C., Bonito, A. J., Steinman, R. M. (2004) The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J. Exp. Med. 199, 1607-1618.
37. Gong, D., Malek, T. R. (2007) Cytokine-dependent Blimp-1 expression in activated T cells inhibits IL-2 production. J. Immunol. 178, 242-252.
38. Zhou, Q., Gault, R. A., Kozel, T. R., Murphy, W. J. (2007) Protection from direct cerebral Cryptococcus infection by interferon-{γ}-dependent activation of microglial dells. J. Immunol. 178, 5753-5761.
39. Levitz, S. M. (1991) Activation of human peripheral blood mononuclear cells by interleukin-2 and granulocyte-macrophage colony-stimulating factor to inhibit Cryptococcus neoformans. Infect. Immun. 59, 3393-3397.